Purpose: To determine the effectiveness of stent-grafts for the treatment of central venous disease in hemodialysis patients with functioning arteriovenous (AV) fistulas.
Materials And Methods: Between October 2004 and March 2010, 42 VIABAHN stent-grafts were deployed in central veins of 30 patients (16 men, 14 women; mean age 60 y) with functioning AV fistulas and central venous disease that did not respond to percutaneous transluminal angioplasty (PTA). Eighteen patients had central vein stenosis and 12 had occlusion. Previous PTA and/or bare metal stent placement had been performed in 23 patients (77%). Surveillance was carried out at 3, 6, 9, 12, 18, and 24 months with diagnostic fistulography. The mean follow-up was 705 days (range, 66-1,645 d). Statistical analysis included Kaplan-Meier and log-rank studies.
Results: Technical success rate was 100%. Primary patency rates were 97%, 81%, 67%, and 45% at 3, 6, 12, and 24 months, respectively. Primary assisted patency rates were 100%, 100%, 80%, and 75% at 3, 6, 12, and 24 months, respectively. Patients without previous procedures had significantly shorter times to repeat intervention (P = .018) than those who had undergone PTA or bare metal stent placement previously. Patients with occlusive lesions had a significantly shorter primary patency interval (P = .05) than patients with stenoses. Occluded veins were more likely to require further stent-grafts (P = .02). Twelve patients required further stent-grafts to maintain patency. There was one minor complication.
Conclusions: Stent-graft placement to treat central venous disease in hemodialysis patients with autogenous AV fistulas is safe and effective if PTA fails to maintain luminal patency.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvir.2011.06.002 | DOI Listing |
J Appl Lab Med
January 2025
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Background: Hyperaldosteronism involves complex, multidisciplinary management, including clinical testing, radiological exams, and adrenal venous sampling (AVS). This study assesses AVS outcomes at a large referral center, focusing on cannulation success, lateralization of aldosterone-producing adenomas, and correlation with radiological and surgical findings.
Methods: A retrospective review of 153 patients who underwent AVS from September 2016 to January 2024 was conducted.
J Vasc Access
January 2025
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Background: Central venous access devices (CVAD) are widely used in patient care, providing an essential, reliable pathway for patients to receive chemotherapy, long-term infusions, and nutritional support. However, a system of exercise management has not been developed in patients with CVAD.
Purpose: To evaluate and summarize the evidence for management exercise in patients with CVAD and provide guidance for clinical practice.
Sci Rep
January 2025
Medical Oncology Department, Central University Hospital of Asturias, Oviedo, Spain.
Totally implantable central venous catheters (CVCs) are widely used in the management of patients with malignant diseases. Conventionally, port implantations were carried out by general surgeons and vascular radiologists. In recent years, the medical staff of the Medical Oncology department at the Central University Hospital of Asturias (HUCA) has developed a simplified methodology for the routine implantation of these devices.
View Article and Find Full Text PDFEur J Surg Oncol
January 2025
Division of Surgical Oncology, Department of Surgery - University of Colorado Anschutz Medical Campus, Denver, USA.
Background: Pancreatectomy with venous resection (PVR) is nowadays considered standard. However, there is still concern about increased postoperative morbidity and impaired long-term outcome depending on the type of venous resection and reconstruction. The aim was to investigate the predictors of morbidity and long-term survival in patients undergoing PVR in a high-volume center.
View Article and Find Full Text PDFInvest Radiol
January 2025
From the Department of Radiology, Ulsan University Hospital, Ulsan, Republic of Korea (T.Y.L.); Department of Radiology, University of Ulsan College of Medicine, Seoul, Republic of Korea (T.Y.L.); Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea (J.H.Y., H.K., J.M.L.); Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea (J.H.Y., S.H.P., J.M.L.); Department of Radiology, Inje University Busan Paik Hospital, Busan, Republic of Korea (J.Y.P.); Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea (S.H.P.); Department of Radiology, Hanyang University College of Medicine, Seoul, Republic of Korea (C.L.); Division of Biostatistics, Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea (Y.C.); and Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea (J.M.L.).
Objective: The aim of this study was to intraindividually compare the conspicuity of focal liver lesions (FLLs) between low- and ultra-low-dose computed tomography (CT) with deep learning reconstruction (DLR) and standard-dose CT with model-based iterative reconstruction (MBIR) from a single CT using dual-split scan in patients with suspected liver metastasis via a noninferiority design.
Materials And Methods: This prospective study enrolled participants who met the eligibility criteria at 2 tertiary hospitals in South Korea from June 2022 to January 2023. The criteria included (a) being aged between 20 and 85 years and (b) having suspected or known liver metastases.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!